Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHEP-BV Followed by BV Consolidation in CD30-Positive PTCL
NCT03113500Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2017
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), sponsored by City of Hope. Primary endpoint: Complete Response Rate. Started May 2017; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03113500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113500.